Greencore up 11% on strong trading; Bakkavor deal on track

Greencore Group PLC shares surged 11% after reporting a 9.9% increase in Q3 revenue to £511.1 million, driven by robust demand and operational efficiencies, leading the company to raise its full-year profit guidance to between £118 million and £121 million. Concurrently, Bakkavor Group PLC gained 6% as Greencore confirmed its planned acquisition of Bakkavor remains on track for early 2026, pending regulatory approval, signaling positive sector momentum and progress on a significant M&A deal.

Analysis

Greencore Group PLC (LSE:GNC) demonstrated robust operational and financial health, precipitating an 11% surge in its share price. The company reported a 9.9% year-over-year increase in third-quarter revenue to £511.1 million, critically supported by a 3.6% rise in volumes which outpaced the broader grocery market. This top-line strength was driven by strong consumer demand in core categories like sandwiches and ready meals, alongside successful new product introductions. Importantly, the growth was profitable, with operational efficiencies and cost controls leading to profit conversion that surpassed management's expectations. This performance provided the confidence to raise the full-year profit guidance to a range of £118-£121 million. Concurrently, the positive sentiment extended to Bakkavor Group PLC (LSE:BAKK), which saw its shares rise 6%, as Greencore reaffirmed that its planned acquisition of Bakkavor is on track for completion in early 2026, contingent on regulatory approval.

Key Decisions for Investors

• Greencore's strong organic performance, evidenced by revenue growth that outpaces the market and expanding profit margins, validates its operational strategy and supports the upward revision of its full-year guidance, suggesting continued fundamental strength.
• For Bakkavor, the investment case is now predominantly tied to the successful completion of the Greencore acquisition, meaning investors should closely monitor progress and any announcements related to the regulatory approval process as the key catalyst.
• While the M&A synergy is a positive signal, investors should remain cognizant of the execution risk and the explicit contingency of regulatory approval, which remains the primary hurdle before the deal's expected close in early 2026.